|London and New York -- December 27, 2018 -- InvestorsHub NewsWire -- Trafalgar Research Group initiates coverage on the growing cannabis and CBD sector, that is experiencing a massive global growth phenomenon. According to Arcview Market Research and its research partner BDS Analytics, over the next 10 years, the legal cannabis industry will see much progress around the globe. Spending on legal cannabis worldwide is expected to hit $57 billion by 2027. The adult-use (recreational) market will cover 67% of the spending; medical marijuana will take up the remaining 33%.
The largest group of cannabis buyers will be in North America, going from $9.2 billion in 2017 to $47.3 billion a decade later. The largest growth spread, however, is predicted within the rest-of-world markets, from $52 million spent in 2017 to a projected $2.5 billion in 2027.
Mr. Oscar Brito, President stated: “On or around May of 2018, management decided to focus its resources towards the legalized cannabis industry. Our business plan is to leverage our extensive experience in real estate financing and development while establishing JV partnerships to acquire and operate facility’s or real estate-based cannabis operations. We don’t have the industry expertise to operate a cannabis facility, but we do have extensive experience in construction, acquisition development, financing and repositioning of real estate assets.”
The worldwide adult recreational cannabis market remains hampered by the United Nations and its 1961 Single Convention on Narcotic Drugs. The Arcview and BDS report believes nothing will be done to change the U.N. attitude until U.S. federal laws legalize marijuana — something Arcview’s CEO, Troy Dayton, believes will happen after the 2020 presidential election.
Still, the main difference between the U.S. and European cannabis markets is that in the U.S., recreational use will dominate sales. With a budget of $1.3 trillion in health care spending, European government-subsidized health care systems will bring the medical cannabis market to dominate Europe and become the largest medical marijuana market in the world.
For years, experts have predicted that if the cannabis industry expands at its current rate, the American market will reach $20 billion by 2020. But it turns out that one market is spinning off into a mega-industry of its own: according to a new estimate from cannabis industry analysts the Brightfield Group, the hemp-CBD market alone could hit $22 billion by 2022.
CBD, a non-psychoactive cannabinoid found in cannabis, has had a surge in popularity over the past couple of years. Unlike THC, the chemical compound that gives weed its signature effect, CBD has been shown to help with everything from PTSD and anxiety to MS and epilepsy — without getting you high.
Previously, CBD products have been available mostly in head shops, with a few doctors recommending it for various maladies. But in 2017 and 2018, the products spread to natural food stores, beauty aisles, cafés and doctors offices. So far the industry is on track to hit $591 million in 2018, and thanks to a number of factors — including, surprisingly, Senate Majority Leader Mitch McConnell — that could increase 40 times in the next four years.
Trafalgar Research has added MSPC along with the following companies for coverage:
Metrospaces, Inc. (OTC: MSPC) yesterday announced that it has entered into a Joint Venture LOI with DLBCC Group to acquire an ongoing profitable cannabis facility and will operate such.
“We are very excited with this Joint Venture LOI agreement with DLBCC Group to acquire, operate and grow this facility. DLBCC Group has executed a Property Purchase Agreement with the seller and is set to close in approximately 90 days.”
A final JV agreement and Purchase Agreement is contingent on transfer of license and senior acquisition funding. Metrospaces would provide the equity portion of the acquisition, agreed at $20 million. Metrospaces would retain 75% of the business initially, LBCC Group can obtain an additional 10% equity stake based on achievement of certain financial goals."
The facility is located in the city of Adelanto, California and consists of a 12,000 ft. two canopy facility licensed for cultivation, manufacture and distribution of approximately 300 lbs monthly production. The production currently generates approximately $7.2 million in annual revenue with an operating profit of approximately $4.5 million per year. Additionally, the site is set on a 6.5 acres which would allow for another (already licensed) 8,000 ft 2 canopy. The acquisition also includes a non-operating retail location.
Medical Marijuana Inc. (OTCBB: MJNA) is the first publicly held company vested in the cannabis and industrial hemp space in America. Through its subsidiaries and investment holdings the Company focuses on the development, sale and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol ("CBD") and other products containing CBD-rich hemp oil ("Legal Hemp"). Company products are formulated for the pharmaceutical, nutraceutical and cosmeceutical industries, including dietary supplements, prescription-based hemp oil for sale in countries that have legalized our hemp oil for the treatment of various illnesses and conditions (such as Brazil and Mexico) and skin care products. The Company is not in the business of selling or dispensing either recreational or medical marijuana, directly or indirectly, so long as marijuana remains a federally controlled substance, however, we are poised and consider ourselves well-positioned for eventual cannabis legalization (the Company's products contain only those substances that are derived from the part of the cannabis plant that is excluded from the definition of marijuana under the Controlled Substances Act and are both federally legal and outside of the purview of the Drug Enforcement Administration).
Marijuana Company of America, Inc. (OTCBB:MCOA) is a corporation which participates in: (1) product research and development of hemp-based consumer products under the brand name "hempSMART", containing CBD derived from Industrial Hemp targeting general health and well-being; (2) an affiliate marketing program to promote and sell its "hempSMART" consumer products; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis and/or Industrial Hemp in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in these segments mature and develop.
Puration, Inc. (OTCBB:PURA) has been a water purification company that designs, develops, engineers, produces, markets, and distributes personal and group systems that filter, purify, clean, extract or otherwise improve the quality of water on a cost effective, affordable basis, with a minimum of environmental impact. Resulting from our own design and engineering, our water purification systems include personal water filter bottles, collapsible water pouches, replacement filters, and travel filters. While the Company carries a current inventory of personal water filter bottles and collapsible water pouches and that inventory is availed for sale at select retail locations, the Company has in the last year begun to explore and develop new business opportunities focusing on the emerging Cannabis Extractions Sector. In July 2015, the Company entered into an agreement to acquire certain health & wellness joint ventures from North American Cannabis Holdings, Inc. (USMJ).
Trafalgar Research Group (TRG) produces non-sponsored and non-paid coverage, reports and articles on small and micro-cap equities listed on NASDAQ and OTC exchanges. TRG has not been compensated directly or indirectly for producing or publishing this coverage. TRG does not hold a position in any of the securities covered in this release directly or indirectly. The content contained herein has been prepared by a research writer and is fact checked and reviewed based on publicly available information which is believed to be reliable. The content is researched, written, and reviewed on a best-effort basis. The writer has not performed any independent investigations or authentication of audits to validate the information herein. The content has not been reviewed by a registered analyst. TRG, the writer, and or the reviewer are not responsible for any error which may occur at the time of publishing this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TRG, the writer, and or reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TRG, the writer, and or the reviewer do not guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or warrant any results from use of the information.
THIS IS NOT AN OFFERING
This coverage release is not intended as an offering, recommendation, or a solicitation or an offer to buy or sell the securities mentioned or discussed,and is to be used for informational purposes only. Please read all disclosures and disclaimers in full. TRG or any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction.
For any questions, inquiries, or comments please contact us. If you are a company we cover and would like to be removed, please contact us via email at:
SOURCE: Trafalgar Research Group